FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308571877> ?p ?o ?g. }

• W4308571877 abstract "The approved dose of nivolumab is 3 mg/kg or a flat dose of 240 mg for indications. There is no dose-response relationship for nivolumab; therefore, a low-dose regimen may be an option to reduce financial toxicity. This study was designed to investigate the efficacy and safety of low-dose nivolumab in the management of hepatocellular carcinoma (HCC).We retrospectively reviewed patients with HCC who received 20 or 100 mg of nivolumab intravenously every 2 weeks. The objective response rate was determined in accordance with the Response Evaluation Criteria in Solid Tumors criteria version 1.1. The Cox regression model and Kaplan-Meier method were used to analyze hazard factors, progression-free survival (PFS), and overall survival (OS). Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.In total, 78 patients were enrolled, including 49 with hepatitis B virus (HBV) and 23 with hepatitis C virus (HCV). All patients were staged as Barcelona Clinic Liver Cancer stage C, and 20 patients were classified as having Child-Pugh classification B (7). Nivolumab 20 mg was an independent prognostic factor for better PFS, and albumin-bilirubin grade 1 was the independent prognostic factor for superior OS in the multivariate analyses. Patients with better HBV (HBV DNA < 500 IU/ml) and HCV (HCV RNA undetectable) controls had superior OS. All AEs were grade 1-2 in severity, and all patients tolerated nivolumab without treatment interruption or dose adjustment. Additionally, 31 patients underwent subsequent therapy after nivolumab treatment.Low-dose nivolumab may be effective with manageable toxicity and can be an alternative option to reduce financial toxicity in patients with advanced HCC who cannot afford the high cost of immune checkpoint inhibitors in real-world practice." @default.
• W4308571877 created "2022-11-12" @default.
• W4308571877 creator A5001467169 @default.
• W4308571877 creator A5006839087 @default.
• W4308571877 creator A5016683607 @default.
• W4308571877 creator A5020114965 @default.
• W4308571877 creator A5024318722 @default.
• W4308571877 creator A5040415788 @default.
• W4308571877 date "2022-11-08" @default.
• W4308571877 modified "2023-10-15" @default.
• W4308571877 title "Low-dose nivolumab in advanced hepatocellular carcinoma" @default.
• W4308571877 cites W1971837077 @default.
• W4308571877 cites W1994193851 @default.
• W4308571877 cites W2019607817 @default.
• W4308571877 cites W2039178409 @default.
• W4308571877 cites W2119190881 @default.
• W4308571877 cites W2147172608 @default.
• W4308571877 cites W2148706732 @default.
• W4308571877 cites W2160834915 @default.
• W4308571877 cites W2560367415 @default.
• W4308571877 cites W2560499218 @default.
• W4308571877 cites W2591717879 @default.
• W4308571877 cites W2605644052 @default.
• W4308571877 cites W2606367731 @default.
• W4308571877 cites W2615652585 @default.
• W4308571877 cites W2625856057 @default.
• W4308571877 cites W2744914748 @default.
• W4308571877 cites W2753432434 @default.
• W4308571877 cites W2787358630 @default.
• W4308571877 cites W2796067155 @default.
• W4308571877 cites W2796582438 @default.
• W4308571877 cites W2805592007 @default.
• W4308571877 cites W2809889937 @default.
• W4308571877 cites W2882999865 @default.
• W4308571877 cites W2898074532 @default.
• W4308571877 cites W2908573150 @default.
• W4308571877 cites W2945590213 @default.
• W4308571877 cites W2948172856 @default.
• W4308571877 cites W2966187720 @default.
• W4308571877 cites W3025022288 @default.
• W4308571877 cites W3043703771 @default.
• W4308571877 cites W3049327094 @default.
• W4308571877 cites W3090413519 @default.
• W4308571877 cites W3120123676 @default.
• W4308571877 cites W3165752903 @default.
• W4308571877 cites W4210243841 @default.
• W4308571877 cites W996817436 @default.
• W4308571877 doi "https://doi.org/10.1186/s12885-022-10271-6" @default.
• W4308571877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36348292" @default.
• W4308571877 hasPublicationYear "2022" @default.
• W4308571877 type Work @default.
• W4308571877 citedByCount "4" @default.
• W4308571877 countsByYear W43085718772023 @default.
• W4308571877 crossrefType "journal-article" @default.
• W4308571877 hasAuthorship W4308571877A5001467169 @default.
• W4308571877 hasAuthorship W4308571877A5006839087 @default.
• W4308571877 hasAuthorship W4308571877A5016683607 @default.
• W4308571877 hasAuthorship W4308571877A5020114965 @default.
• W4308571877 hasAuthorship W4308571877A5024318722 @default.
• W4308571877 hasAuthorship W4308571877A5040415788 @default.
• W4308571877 hasBestOaLocation W43085718771 @default.
• W4308571877 hasConcept C121608353 @default.
• W4308571877 hasConcept C126322002 @default.
• W4308571877 hasConcept C143998085 @default.
• W4308571877 hasConcept C197934379 @default.
• W4308571877 hasConcept C203014093 @default.
• W4308571877 hasConcept C207103383 @default.
• W4308571877 hasConcept C2522874641 @default.
• W4308571877 hasConcept C2776408679 @default.
• W4308571877 hasConcept C2776455275 @default.
• W4308571877 hasConcept C2776694085 @default.
• W4308571877 hasConcept C2777382497 @default.
• W4308571877 hasConcept C2777701055 @default.
• W4308571877 hasConcept C2777793932 @default.
• W4308571877 hasConcept C2778019345 @default.
• W4308571877 hasConcept C2778822529 @default.
• W4308571877 hasConcept C2779984678 @default.
• W4308571877 hasConcept C2780030458 @default.
• W4308571877 hasConcept C2780140570 @default.
• W4308571877 hasConcept C2780593183 @default.
• W4308571877 hasConcept C2781413609 @default.
• W4308571877 hasConcept C44249647 @default.
• W4308571877 hasConcept C50382708 @default.
• W4308571877 hasConcept C71924100 @default.
• W4308571877 hasConcept C90924648 @default.
• W4308571877 hasConceptScore W4308571877C121608353 @default.
• W4308571877 hasConceptScore W4308571877C126322002 @default.
• W4308571877 hasConceptScore W4308571877C143998085 @default.
• W4308571877 hasConceptScore W4308571877C197934379 @default.
• W4308571877 hasConceptScore W4308571877C203014093 @default.
• W4308571877 hasConceptScore W4308571877C207103383 @default.
• W4308571877 hasConceptScore W4308571877C2522874641 @default.
• W4308571877 hasConceptScore W4308571877C2776408679 @default.
• W4308571877 hasConceptScore W4308571877C2776455275 @default.
• W4308571877 hasConceptScore W4308571877C2776694085 @default.
• W4308571877 hasConceptScore W4308571877C2777382497 @default.
• W4308571877 hasConceptScore W4308571877C2777701055 @default.
• W4308571877 hasConceptScore W4308571877C2777793932 @default.
• W4308571877 hasConceptScore W4308571877C2778019345 @default.
• W4308571877 hasConceptScore W4308571877C2778822529 @default.

• next